iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

iRhythm Technologies reports strong Q4 results and eyes global expansion

iRhythm Technologies' Q4 2024 performance reflects robust revenue growth, operational efficiency improvements, and strategic milestones in patient registrations. The company's strengths lie in its innovative approach to healthcare solutions, global expansion efforts, and strong financial position. While facing challenges in FDA compliance, potential tariffs impact, and operational targets for 2025, iRhythm is well-positioned to capitalize on growth opportunities.

iRhythm Technologies excels in Q1 2025, raises guidance and expands globally

iRhythm Technologies delivered robust financial performance in Q1 2025, driven by strategic initiatives and market expansion. The company's strong revenue growth, increased guidance, and confidence in growth strategy highlight its positive outlook. While facing operational challenges and potential risks, iRhythm remains well-positioned to capitalize on opportunities for further growth.

iRhythm Technologies excels in Q2, raises full-year guidance on strong performance

iRhythm Technologies delivered a robust Q2 performance with revenue growth, margin improvement, and raised full-year guidance, showcasing operational strength and market potential. The company's strategic focus on core business, product innovation, and international expansion positions it well for continued success and growth. While challenges in competition, regulation, and operational efficiency exist, iRhythm's strong financial position and market opportunities offer a promising outlook.

iRhythm Technologies excels in Q3, raises full-year revenue guidance

iRhythm Technologies delivered robust financial results in Q3 2025, with strong revenue growth and margin performance, raising full-year revenue guidance. The company's strategic focus on EHR integration, early detection, and innovative partnerships positions it well for sustained growth and market leadership. While facing challenges in maintaining margins and navigating competition, iRhythm has opportunities to expand its reach, drive innovation, and improve patient care.

iRhythm Technologies posts strong Q4 results, targets $1B revenue by 2027

iRhythm Technologies reported robust financial results in Q4 2025, with strong revenue growth, expanded margins, and improved EBITDA, reflecting a solid operational performance. The company's strategic vision to become a $1 billion company by 2027 underscores its commitment to sustainable growth, innovation, and creating long-term value. While facing challenges in achieving its ambitious targets, iRhythm is well-positioned to capitalize on opportunities through innovation, international expansion, and operational efficiency.

iRhythm Technologies excels in Q1, raises full-year guidance

iRhythm Technologies' Q1 performance reflects strong revenue growth, margin expansion, and strategic advancements. While facing challenges like negative cash flow and regulatory issues, the company is well-positioned to capitalize on opportunities in AI, primary care, and international markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Holdings, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.